Clinical trials: Second-Line
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced gastric…
- Trial name
- NCT01095120
- Testing
- Tesetaxel
- Where
- 4 sites in United States, South Korea
- Volunteers
- 27 people
- Sponsor
- Genta Incorporated
GastroEsophageal Cancer
Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer
Combining Erb inhibitors, such lapatinib, and TS inhibitors, such as capecitabine, may be a beneficial contribution to current treatment paradigms since preclinical data suggest that lapatinib alone can decrease TS mRNA and is…
- Trial name
- GastroLap (NCT01145404)
- Testing
- Lapatinib, Lapatinib plus capecitabine
- Where
- 16 sites in Germany
- Volunteers
- 76 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Colorectal Cancer
Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer
The objectives of this study are to evaluate the efficacy and tolerability of single-week regimen of irinotecan plus capecitabine in the first-line or second-line treatment of advanced colorectal cancer.
- Trial name
- NCT01322152
- Testing
- irinotecan, capecitabine
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Colorectal Cancer Metastatic, KRAS G12C Mutation
The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer
This is an open-label, multicenter, single-arm Phase II clinical study, divided into subgroups A and B: Cohort A - To evaluate the efficacy and safety of IBI351, cetuximab β combined with FOLFIRI as first-line treatment for…
- Trial name
- cruciall (NCT06959589)
- Testing
- IBI351, cetuximab β combined with FOLFIRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Endometrial Neoplasms
Lenvatinib in Second Line Endometrial Carcinoma
The primary objective of this multicenter, randomized phase II trial is to assess the efficacy, as measured by progression-free survival (PFS), of lenvatinib compared to doxorubicin in advanced or recurrent endometrial cancer.
- Trial name
- NCT03005015
- Testing
- Lenvatinib, Doxorubicin
- Where
- Switzerland
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non Small Cell Lung Cancer
Third-line Treatment of Gefitinib in NSCLC Patients
The purpose of this study is to evaluate the disease control rate (DCR) of gefitinib as third-line retreatment in stage IIIB/IV NSCLC with EGFR 19del/L858R positive mutation patients who had benefited from first-line gefitinib…
- Trial name
- NCT01933347
- Testing
- Gefitinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Guangdong Association of Clinical Trials
Small Cell Lung Carcinoma
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC…
- Trial name
- NCT04938817
- Testing
- coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830
- Where
- 48 sites in United States, Australia and 10 more
- Volunteers
- 110 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
The purpose of this study is to determine whether the addition of bevacizumab to Abraxane as second-line therapy in Her-2 negative, hormone receptor negative metastatic breast cancer.
- Trial name
- NCT00472693
- Testing
- Bevacizumab, Abraxane
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Colorectal Cancer
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
The main objective is to evaluate progression-free survival (PFS) at 4 months. The secondary objectives are to evaluate the objective response rate (OR) (= complete responses (CR) and partial responses (PR)) according to the…
- Trial name
- NCT01442649
- Testing
- Oxaliplatin, Folinic Acid, 5-fluoro-uracil
- Where
- France
- Volunteers
- 133 people
- Sponsor
- UNICANCER
Colorectal Carcinoma
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
This study is designed to compare the efficacy and safety of two-weekly RAILIRI regimen with FOLFIRI regimen in the treatment of advanced colorectal cancer patients in the second-line setting.
- Trial name
- NCT02376452
- Testing
- Raltitrexed, Irinotecan, 5-fluorouracil
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Advanced Pancreatic Cancer (Part 1)
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
Purpose of the study Phase I study: to explore the optimal dose combination of irinotecan liposome + oxaliplatin + bevacizumab regimen, irinotecan liposome + oxaliplatin Phase II study: to evaluate the safety and efficacy of the…
- Trial name
- NCT06782685
- Testing
- Irinotecan liposoma, oxaliplatin, bevacizumab
- Where
- 2 sites in China
- Volunteers
- 138 people
- Sponsor
- Dai, Guanghai
Non Small Cell Lung Cancer
Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
To compare the efficacy of pegilodecakin in combination with nivolumab versus nivolumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.
- Trial name
- Cypress 2 (NCT03382912)
- Testing
- Pegilodecakin, Nivolumab
- Where
- 35 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
PEG-rhG-CSF, Pancreatic Cancer
PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer
A prospective, open, single-arm clinical study to evaluate the efficacy and safety of jinyouli（PEG-rhG-CSF） in the first-line treatment of advanced pancreatic cancer with nab-paclitaxel combined with S-1.Chemotherapy regimen: (1)…
- Trial name
- NCT04518800
- Testing
- Jin Youli(PEG-rhG-CSF)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Nasopharyngeal Carcinoma (NPC)
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
The study is to explore the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic Nasopharyngeal Carcinoma (NPC) who failed or are intolerant to…
- Trial name
- NCT06839066
- Testing
- HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3
- Where
- 15 sites in China
- Volunteers
- 70 people
- Sponsor
- Shanghai Henlius Biotech
Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Outpatient Epcoritamab in Large B-cell Lymphoma
The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.
- Trial name
- NCT06811272
- Testing
- Epcoritamab, Rituximab combined with cyclophosphamide, vincristine, and prednisone, Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Advanced Breast Cancer
E3 Breast Cancer Taxotere Combination
To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology
- Trial name
- NCT00494481
- Testing
- Vandetanib (ZD6474), Docetaxel
- Where
- 12 sites in Hungary, South Africa and 3 more
- Volunteers
- 64 people
- Sponsor
- Genzyme, a Sanofi Company
Metastatic Colorectal Cancer
Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer
Colorectal cancer is the third most frequent neoplasm after prostate and lung in man and breast and lung cancers in woman from Western Countries.
- Trial name
- ARBITRATION (NCT04397601)
- Testing
- Folfiri/Bevacizumab, Folfiri/Aflibercept
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- National Cancer Institute, Naples
Urothelial Cancer
The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium
A study to determine the efficacy of Everolimus(Afinitor®) as third line therapy in patients with transitional cell carcinoma of the urothelium which failed or progressed after two lines of chemotherapy
- Trial name
- AFINIVEST (NCT01801137)
- Testing
- Everolimus (Afinitor®)
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Hopital Foch
Overactive Bladder, Diversity
Diversity in Patients With OAB
An overactive bladder (OAB) is a condition characterized by frequent en nightly voiding, small bladder capacity and the occurrence of sudden urge to void, with or without urinary incontinence.
- Conditions
- Overactive Bladder, Diversity, Onabotulinum Toxin A, Sacral Neuromodulation
- Trial name
- DOAB (NCT05903105)
- Testing
- Questionnaires
- Where
- Belgium
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Ghent
Crohn Disease
Efficacy and Safety Comparison of Upadacitinib and Vedolizumab in Second-line Treatment for Crohn's Disease
This study focuses on Upadacitinib, a new oral and small-molecular medication that inhibits specific enzymes involved in inflammation.
- Trial name
- NCT06446219
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.